Introduction: The highly selective a 2 -agonist dexmedetomidine has become a popular sedative for neurointensive care
The effects of dexmedetomidine, propofol, S-ketamine, and sevoflurane on the regional cerebral metabolic rate of glucose (CMR glu ) were compared at equi-sedative doses. All but S-ketamine reduced cerebral metabolic rate relative to placebo with relative potencies of dexmedetomidine>propofol>ketamine¼placebo. Sevoflurane decreased metabolism equally to propofol but the dose was not quite equipotent. These findings alleviate concerns for harmful effects of dexmedetomidine on the ratio of cerebral blood flow and metabolism.
Different anaesthetics produce characteristic effects on cerebral blood flow (CBF) and metabolism. While sevoflurane decreases cerebral metabolism more than CBF, 1e4 propofol induces a proportional decrease in both measures. 1e3,5e11 For this reason, propofol has been deemed particularly suitable for neurosurgical and neurointensive care patients. S-ketamine has been demonstrated to increase glucose metabolism in certain regions of the brain and to induce a global increase in CBF. 12e14 Although dexmedetomidine has become a popular sedative for neurointensive care patients, its effects on cerebral glucose metabolism have not been properly characterised in humans.
Dexmedetomidine is an a 2 -adrenoceptor agonist with unique properties; it induces sufficient sedation while allowing patient arousal and awakening without changing infusion rate. This is a valuable feature, especially in intensive care patients, who need frequent assessment of their neurological state. In addition, dexmedetomidine has mild analgesic properties and minimal respiratory effects. Furthermore, experimental studies have suggested neuroprotective properties of dexmedetomidine, 15 but this has not been established in humans. 16 In early animal studies, dexmedetomidine was found to reduce CBF with no effect on the cerebral metabolic rate of oxygen. 17, 18 This raised concern that the decreased blood flow might be inadequate for the cerebral metabolic needs. Studies in humans have, however, suggested that dexmedetomidine proportionally decreases CBF and oxygen metabolism. 19, 20 Nevertheless, uncertainty remains on this issue. We compared the effects of dexmedetomidine, propofol, sevoflurane, S-ketamine, and placebo on the regional cerebral metabolic rate of glucose (CMR glu ) with high-resolution positron emission tomography (PET) imaging. Our aim was to establish the relative potencies of these four anaesthetics with different mechanisms of action, all given at equi-sedative doses.
Methods

Trial design and participants
We conducted an open-label, randomised, controlled, parallel group, phase IV clinical drug trial at the Turku PET Centre, University of Turku, Finland. The study (ClinicalTrials.gov Identifier NCT02624401) was approved by the Ethics Committee of the Hospital District of Southwest Finland and the Finnish Medicines Agency Fimea (EudraCT 2015-004982-10).
Inclusion criteria were male sex, age 18e30 yr, normal hearing, right handedness, good sleep quality, ASA physical status class 1, fluency in the Finnish language and normal results in a thorough physical examination and laboratory tests including drug screening. Use of any medication or alcohol was prohibited for 48 h and caffeine products for 10e12 h before the study session. All subjects fasted from the previous midnight. Written informed consent was obtained from all subjects according to the Declaration of Helsinki.
The goal was to have 160 (n¼40 in each group, except n¼20 in the S-ketamine and placebo groups) subjects with complete data, and because of 20 premature withdrawals or dropouts (see Results), 180 subjects were recruited. Subjects were randomised with balanced permuted block sizes of 16 to receive either dexmedetomidine (Dexdor 100 mg ml À1 ; Orion Pharma, Espoo, Finland), propofol (Propolipid 10 mg ml À1 ; Fresenius Kabi, Uppsala, Sweden), sevoflurane (Sevorane 100%; Abbvie, Espoo, Finland), S-ketamine (Ketanest-S 25 mg ml À1 ; Pfizer, Helsinki, Finland) or saline placebo. The person (H.S.) responsible for randomisation did not recruit the subjects to ensure random allocation of the treatments. Baseline characteristics of the subjects are shown in Table 1 .
Anaesthetic protocol and monitoring
A radial artery was cannulated for all blood samplings and two forearm venous catheters were placed for administration of anaesthetics and Ringer's acetate (at a standard rate of~100 ml h À1 ), and The study outline and sequence of events are shown in Fig. 1 . The drug administration protocol included a 20 min stabilisation phase, followed by a 40 min pseudosteady-state phase. I.V. anaesthetics were administered using targetcontrolled infusion with a Harvard 22 syringe pump (Harvard Apparatus, South Natick, MA, USA) connected to a portable computer running Stanpump software (www.opentci.org/ code/stanpump) with previously reported pharmacokinetic parameters. 21e23 In each of the drug groups, the aim was to achieve a sample where 50% of subjects were unresponsive and 50% maintained responsiveness, defined as the 50% 24 Sevoflurane group subjects wore a face mask tightened with a rubber strap with fresh gas flow set at 6 L min À1 . After 60 min of drug administration, subjects were transferred to the PET scanner room for a 30 min PET scan (see below). Peripheral oxygen saturation, ECG, and end-tidal carbon dioxide were monitored continuously during the study. Blood pressure was measured non-invasively at the beginning and end of drug administration to avoid possible cuff pain and ensuing arousal during PET data acquisition. A Datex-Ohmeda S/5 anaesthesia monitor (Datex-Ohmeda Division, Instrumentarium Corp., General Electric Company, Helsinki, Finland) and a portable computer running the S5 Collect software (Collect version 4.0, GE Healthcare) were used to record and store all vital parameters.
Subjects were classified as responsive or unresponsive by asking them to press a custom-made handle secured on both wrists. A prerecorded request 'press the handles twice' was delivered via headphones using the Presentation 17.0 stimulus delivery and experimental control software system (Neurobehavioral Systems Inc, Berkeley, CA, USA). Testing was considered to be stabilised, administration of anaesthetic was terminated, and a 30 min PET scan was performed followed by a transmission scan using a High Resolution Research Tomograph, a dual-layer crystal-detector scanner with an isotropic 2.5 mm intrinsic spatial resolution (HRRT; Siemens Medical Solutions, Knoxville, TN, USA). 26, 27 The time lag between the end of anaesthesia and the start of PET scanning was 5e10 min. All study sessions were conducted in a quiet, dimly lit room. PET emission data acquisition in list-mode format was initiated approximately 45e50 min after tracer injection. The subject's head was fixed to the headrest of the scanner with an individual thermoplastic mask made before the scanning. Head motion was monitored using a high-precision, stereotactic tracking device (Polaris Vicra; Northern Digital, Waterloo, Ontario, Canada) attached to the subject's head. Image formation was conducted using an iterative OP-OSEM algorithm with resolution modelling (12 iterations, 16 subsets, including corrections for attenuation, scatter, and random events). 28 PET emission data were histogrammed into a single 30 min frame reflecting the assumption of steady [
18 F]FDG retention at this late time window. If a head movement >2.5 mm was detected, scans were divided into subframes and subsequently co-registered into a single 30 min frame by using the multiple acquisition frame image reconstruction procedure and the attenuation correction realignment algorithm. 29 This procedure was used in four dexmedetomidine scans, two S-ketamine scans, and two sevoflurane scans.
Twenty-four arterial tracer activity blood samples were collected for tracer kinetic modelling. Voxel-average, regional CMR glu values were extracted within 15 ROIs including the prefrontal cortex, parietal cortex, lateral temporal cortex, lateral occipital cortex, precuneus, anterior cingulate gyrus, posterior cingulate gyrus, entorhinal cortex, striatum, cerebellum, insula, thalamus, amygdala, pallidum, and hippocampus. ROIs were generated automatically with the help of individual T1-weighted MRI data and FreeSurfer software (version 5.3; http://surfer.nmr.mgh. harvard.edu/; see Supplementary material).
Statistical analyses
The statistical analyses of regional CMR glu data were performed with analysis of variance (ANOVA). First, all regions were analysed together using repeated measures ANOVA with region as a within factor and treatment as a between factor. If a 
Results
Of 180 subjects recruited, 15 withdrew from the study after randomisation. Four sessions (three with S-ketamine, one with sevoflurane) had to be terminated because of excessive motor anxiety. In addition, one subject received only approximately 7% of the planned S-ketamine dose because of a programming error and was therefore excluded. Otherwise, the study was completed as planned. No clinically significant changes were observed in vital parameters (data not shown).
One hundred and sixty subjects were evaluable (40 dexmedetomidine, 40 propofol, 40 sevoflurane, 20 S-ketamine, and 20 placebo) for regional CMR glu . Measured dexmedetomidine and S-ketamine concentrations were somewhat higher than targeted ( Because a significant region by treatment interaction (P<0.001) was found in the repeated measures ANOVA, regions were analysed separately. There were statistically significant differences in regional CMR glu between groups in all 15 ROIs and their aggregate (whole brain CMR glu ; P<0.001 for all; Table 3 , Figs. 2 and 3) . In paired comparisons, the dexmedetomidine, propofol and sevoflurane groups differed from the placebo and S-ketamine groups. Dexmedetomidine was associated with the lowest CMR glu in all brain regions and differed from all other drugs (P<0.05), with the exception that no significant difference was found in the lateral occipital cortex compared with propofol or sevoflurane, and in the cerebellum compared with sevoflurane (Table 3) . Compared with placebo, regional CMR glu values were 30.1e39.6% lower in the dexmedetomidine group. Propofol and sevoflurane did not differ from each other in any ROI. With S-ketamine, CMR glu did not differ from placebo in any of the ROIs studied. There were weak but statistically significant associations between measured drug concentrations and CMR glu in the dexmedetomidine and propofol groups (Fig. 4) .
Discussion
The effects of EC 50 doses for LOR of dexmedetomidine, propofol, sevoflurane, and S-ketamine on absolute CMR glu were evaluated using state-of-the-art PET methodology. Compared with placebo, significantly lower CMR glu values were measured with dexmedetomidine, propofol, and sevoflurane throughout the brain. The greatest suppressive effect was seen with dexmedetomidine, which induced the lowest CMR glu in Fig 2. Boxplots of regional cerebral metabolic rate of glucose (CMR glu ) in the 15 analysed regions of interest (ROIs) during dexmedetomidine, propofol, sevoflurane, S-ketamine, and placebo administration in 160 healthy subjects (P<0.001 between the treatments in all ROIs). Lowest CMR glu values were observed in the dexmedetomidine group (for paired comparisons, see Table 3 ). Boxes represent lower quartiles, medians and upper quartiles, whiskers represent 1.5Âinter-quartile ranges below and above the lower and upper quartiles, respectively. Outlying values are marked with symbols. nearly all brain regions compared with the other groups. With S-ketamine, CMR glu values were comparable with placebo.
Previous studies in laboratory animals and humans have quite consistently demonstrated that dexmedetomidine decreases CBF.
17e19, 32, 33 The most convincing evidence was seen in an early human PET study where a 0.628 ng ml À1 average plasma concentration of dexmedetomidine resulted in a 33% global decrease in CBF from baseline. 32 A reduction in CBF has also been demonstrated with the sagittal sinus outflow technique in two early studies in dogs where dexmedetomidine was given during isoflurane 18 or halothane 17 anaesthesia. The most remarkable finding in these studies was that the decrease in CBF was not associated with a concomitant decrease in cerebral oxygen metabolism, which raised concern that dexmedetomidine might cause ischaemia in the brain. 17, 18 In healthy brain with functional flow-metabolism coupling, a reduction in neuronal activity should be accompanied by a parallel decrease in cerebral metabolism and, consequently, CBF. 34 Dexmedetomidine is known to cause direct vasoconstriction of the cerebral vessels through Boxplots of whole brain cerebral metabolic rate of glucose (CMR glu ) in 160 healthy subjects. CMR glu was 63%, 71%, 71%, and 96% of placebo, in the dexmedetomidine, propofol, sevoflurane, and S-ketamine groups, respectively (P<0.001 between the groups). Dexmedetomidine differed from all other groups (for paired comparisons, see Table 3 ). Boxes represent lower quartiles, medians and upper quartiles, whiskers represent 1.5Âinter-quartile ranges below and above the lower and upper quartiles, respectively. Outlying values are marked with symbols. activation of postsynaptic a 2 -adrenoreceptors on vascular smooth muscle cells, 35 which, in the absence of a concomitant reduction in cerebral metabolism, might predispose the brain to ischaemia. For this reason, a better understanding regarding the effects of dexmedetomidine on brain metabolism is needed. This would have implications for treatment of patients with compromised brain function who are at high risk for cerebral ischaemia. Two small clinical trials have addressed the relationship between brain oxygen utilisation and CBF during dexmedetomidine exposure. By using the middle cerebral artery flow velocity technique and oxygen metabolism equivalent estimation based on jugular vein blood samples, it was demonstrated in six healthy human subjects that dexmedetomidine might decrease cerebral oxygen metabolism equivalently to CBF. 19 Another study showed that dexmedetomidine did not affect brain tissue oxygen concentration in five neurosurgical patients. 36 While these studies were limited by their small sample size, the first study could only offer global relative values and the second study contained many confounding elements including concomitant surgery. Although the latter study could not measure metabolism per se, the preliminary results suggested that dexmedetomidine would not have a direct vasoconstrictive effect that might lead to diminished oxygen delivery to brain tissue.
The most sophisticated previous study on the subject was conducted using combined imaging of CBF with the arterial spin labelling functional MRI technique and [
18 F]FDG-PET. 37 Dexmedetomidine-induced suppression of CBF and CMR glu was observed in the thalamus, the default mode network structures and the frontoparietal regions bilaterally. However, because PET imaging was performed without blood activity sampling, this study could not determine the absolute regional CMR glu effects of dexmedetomidine. The present study resolves this shortcoming and was able to show a significant reduction in absolute regional CMR glu . Given that parallel reductions in CBF have been reported previously, 17e19,32,37 the present results alleviate concern for potential harmful effects of dexmedetomidine on coupling between brain metabolism and perfusion. Numerous studies have shown that propofol and volatile anaesthetics decrease CMR glu , cerebral oxygen metabolism, and CBF. 1e11,38,39 Our results are in line with these previous findings. Ketamine or S-ketamine increase CBF, while their metabolic effects are limited to only a slight increase in certain brain regions. 12e14 Thus, the present results with S-ketamine, with effects on CMR glu comparable with placebo, are also in agreement with previous findings. However, it is noteworthy that the greatest individual variability in CMR glu was observed in the S-ketamine group (Fig. 2) . Here, we provide a definitive answer to anaesthetic potency for reducing CMR glu . Potency for CMRglu reduction in humans follows the rank order of dexmedetomidine>propofol>ketamine¼placebo. Sevoflurane decreased metabolism equally to propofol, but the dose was not quite equipotent.
The main limitation of this study was that CBF was not measured together with CMR glu . Thus, we still lack knowledge of the exact metabolismeperfusion effects of dexmedetomidine. However, the clear reduction in CMR glu observed shows that a parsimonious mode of brain activity can be achieved with dexmedetomidine. Second, only healthy male subjects were investigated. The most concerning issue is the direct vasoconstrictive effect of dexmedetomidine, which might increase the risk of cerebral ischaemia, for example in patients with aneurysmal subarachnoid haemorrhage already vulnerable to vasospasm. Still, reduction in brain activity and CMR glu would probably offer some protection against such an effect. Third, measurements were made for only one target concentration of each of the four anaesthetics. Fourth, our goal of comparing equipotent doses (EC 50 for LOR or MAC LOR ) of anaesthetics was not quite met as 85% of the sevoflurane subjects were unresponsive at the time of [ 18 F]FDG injection, compared with 45e55% in the other drug groups. Despite this shortcoming, CMR glu in the dexmedetomidine group was significantly lower than in the sevoflurane group in the whole brain and in 13 of the 15 ROIs studied.
In conclusion, dexmedetomidine, propofol, and sevoflurane decreased CMR glu in a global manner compared with placebo and S-ketamine, with dexmedetomidine inducing the greatest suppression. The present results alleviate the concern for potential harmful effects of dexmedetomidine on the ratio of cerebral blood flow and metabolism.
